GammaDelta Therapeutics receives FDA Clearance of IND Application for GDX012, a novel allogeneic variable delta 1 gamma-delta T cell cancer therapy

First-in-human clinical study for Acute Myeloid Leukaemia expected to begin [...]

By |2021-05-20T08:20:13+00:00May 20th, 2021|

Paolo Paoletti, CEO of GammaDelta Therapeutics celebrated in the 2019 Maserati 100 Innovators of the year award.

Maserati partners with the Sunday Times to commemorate one hundred [...]

By |2019-10-02T09:03:20+00:00March 25th, 2019|

GammaDelta Therapeutics announced as winner of the 2018 Outstanding Achievement Award at the OBN Annual Awards Ceremony.

GammaDelta Therapeutics announced as winner of the 2018 Outstanding Achievement [...]

By |2019-09-30T15:31:14+00:00October 12th, 2018|
Go to Top